Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    Welcome !
    My account
    Logout

PDL Biopharma Inc (PDLI) Stock Forecast 2025 - AI Price Prediction & Analysis

PDL Biopharma Inc (PDLI) AI Stock Price Forecast & Investment Analysis

PDL Biopharma Inc Stock Price Chart and Technical Analysis

Loading PDL Biopharma Inc interactive price chart and technical analysis...

PDL Biopharma Inc (PDLI) - Comprehensive Stock Analysis & Investment Research

Deep dive into PDL Biopharma Inc's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about PDL Biopharma Inc, including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For PDL Biopharma Inc: PDL Biopharma Inc operates in the Manufacturing sector, making it an emerging small-cap investment.

PDL Biopharma Inc (Stock Symbol: PDLI) is a leading company in the Manufacturing sector , specifically operating within the Biological Product (except Diagnostic) Manufacturing industry.

The organization employs approximately 75 professionals worldwide and operates under the strategic leadership of CEO John McLaughlin.

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing PDL Biopharma Inc's revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For PDL Biopharma Inc: With $52M in annual revenue and -298.0% net margin, the company demonstrates developing profitability.

Annual Revenue: $52 million generating a -298.0% net profit margin .

Market Capitalization: $289 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -28.4% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for PDL Biopharma Inc stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For PDL Biopharma Inc: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for PDL Biopharma Inc stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: PDL Biopharma Inc's competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For PDL Biopharma Inc: Market positioning analysis based on available financial and operational metrics.

PDL Biopharma Inc strategically competes in the highly dynamic Biological Product (except Diagnostic) Manufacturing marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company maintains a healthy 2.7% gross margin, indicating strong pricing power and operational efficiency.

PDL Biopharma Inc (PDLI) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for PDL Biopharma Inc stock analysis.

Loading PDL Biopharma Inc comprehensive fundamental analysis and insider trading data...

Deep dive into PDL Biopharma Inc's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if PDL Biopharma Inc stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For PDL Biopharma Inc: With a P/E ratio of -1.91, the market sees the stock as potentially undervalued.

P/E Ratio -1.91x
P/B Ratio 0.67x
Market Cap $289M
Dividend Yield 4.05%
EPS $-1.29
Book Value/Share $3.68
Revenue/Share $0.44
FCF/Share $-0.14
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently PDL Biopharma Inc converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For PDL Biopharma Inc: An ROE of -28.4% indicates room for improvement in shareholder value creation.

ROE -28.4%
ROA -21.9%
ROIC -24.3%
Gross Margin 2.7%
Operating Margin -139.5%
Net Margin -298.0%
EBT Margin -193.4%
Tax Rate 40.0%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess PDL Biopharma Inc's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For PDL Biopharma Inc: A current ratio of 13.68 indicates strong liquidity.

Current Ratio 13.68x
Quick Ratio 4.53x
D/E Ratio 0.03x
Financial Leverage 1.24x
Interest Coverage -9.7x
Working Capital $268M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal PDL Biopharma Inc's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For PDL Biopharma Inc: Free cash flow of $-57M indicates cash challenges that need attention.

Operating Cash Flow $-56M
Free Cash Flow $-57M
Capital Spending $-1M
OCF Growth YoY -60.1%
FCF Growth YoY -6.8%
FCF/Sales -110.4%
CapEx/Sales 1.6%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively PDL Biopharma Inc uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For PDL Biopharma Inc: An asset turnover of 0.07x suggests room for improvement in asset utilization.

Asset Turnover 0.07x
Receivables Turnover 4.3x
Inventory Turnover 3.5x
Fixed Assets Turnover 10.4x
Days Sales Outstanding 85 days
Days Inventory 105 days
Payables Period 66 days
Cash Conversion Cycle 123 days
Understanding Financial Statement Data

What these metrics mean: Key figures from PDL Biopharma Inc's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For PDL Biopharma Inc: With annual revenue of $52M, PDL Biopharma Inc represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)
Total Revenue $52M
Operating Income $-72M
Net Income $-154M
R&D Expense $17M
SG&A Expense $113M
Cost of Goods Sold $97M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 95%
Cash & Short-term Investments 20%
Total Liabilities 19%
Short-term Debt 10%
Accounts Receivable 11%
Inventory 2%
Dividend & Shareholder Information
Dividends Per Share $0.10
Payout Ratio 23.6%
Shares Outstanding 117M

Latest PDL Biopharma Inc Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting PDL Biopharma Inc (PDLI) stock price and investment outlook.

, source: Benzinga.com

The LENSAR Laser System provides cataract surgeons with the power to execute accurate incisions with unprecedented precision and repeatability. It provides precise capsulotomy incision size, shape and ...

, source: Yahoo Canada Sports

PDL BioPharma, Inc. PDLI reported earnings of 14 cents per share in the third quarter of 2017, surpassing the Zacks Consensus Estimate of 13 cents. The bottom line was also higher than the year-ago ...

, source: The Times of Northwest Indiana

Shares of PDL BioPharma Inc. (NASDAQ: PDLI), a biopharma royalty company, are surging Friday in response to the positive second-quarter earnings report it issued after the bell Thursday. A quarterly ...

, source: Reuters

Jan 5 (Reuters) - Alexion Pharmaceuticals Inc confirmed that its genetic disorder drug Solaris used technology covered by one of PDL BioPharma Inc patents and entered into a $25-million licensing deal ...

PDL Biopharma Inc Competitors & Peer Analysis - Manufacturing Sector

Comparative analysis of PDL Biopharma Inc against industry peers and competitors in the Manufacturing sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio

Frequently Asked Questions - PDL Biopharma Inc Stock Forecast

How accurate are PDL Biopharma Inc stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for PDLI predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence PDL Biopharma Inc stock price forecasts?

Our analysis considers PDL Biopharma Inc's financial metrics, Manufacturing sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is PDL Biopharma Inc a good investment in 2025?

Based on our AI analysis, PDL Biopharma Inc shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are PDL Biopharma Inc forecasts updated?

PDL Biopharma Inc stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced PDL Biopharma Inc Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for PDL Biopharma Inc stock.

🎯 Get Premium Analysis 📊 Explore More Stocks

My Portfolio

Investment Dashboard

Loading your portfolio...